Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Omega Study: Evaluation of the Safety and Efficacy of the Omega System for the Treatment of BPH

NCT: NCT04627701 · ACTIVE_NOT_RECRUITING

NCT IDNCT04627701
StatusACTIVE_NOT_RECRUITING
Start Date2023-07-23
Completion2027-02
SponsorProArc Medical (INDUSTRY)
First posted
Last updated

Brief Summary

The ProArc Medical Omega system is a prostatic reshaping device that is designed to treat Lower Urinary Tract Symptoms (LUTS) due to BPH. During the procedure an implant is delivered into the prostate tissue obstructing the urethra and restricting urine flow. The delivery system uses a static diathermy incision mechanism to make a circumferential incision in the tissue surrounding the prostatic urethra into which the Omega shaped permanent implant is placed. The implant expands the obstructed area, reducing the fluid obstruction through the prostatic urethra.

Frequently Asked Questions

What is Omega Study: Evaluation of the Safety and Efficacy of the Omega System for the Treatment of BPH?

Omega Study: Evaluation of the Safety and Efficacy of the Omega System for the Treatment of BPH is a clinical trial registered under NCT04627701. Current status: ACTIVE_NOT_RECRUITING.

What is the status of NCT04627701?

The current status of NCT04627701 (Omega Study: Evaluation of the Safety and Efficacy of the Omega System for the Treatment of BPH) is: ACTIVE_NOT_RECRUITING.

When did Omega Study: Evaluation of the Safety and Efficacy of the Omega System for the Treatment of BPH start?

Omega Study: Evaluation of the Safety and Efficacy of the Omega System for the Treatment of BPH started on 2023-07-23.

Related Devices

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.